ART27.13 + semaglutide

ART27.13 + semaglutide is an investigational combination therapy consisting of ART27.13, an orally administered, peripherally restricted dual agonist of the cannabinoid CB1 and CB2 receptors, and semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Developed by Artelo Biosciences, the combination is being evaluated for the treatment of obesity. In preclinical diet-induced obesity mouse models, the combination of ART27.13 and semaglutide demonstrated synergistic effects, producing approximately 40% weight loss over four weeks, which is roughly double the weight loss achieved by either agent alone. Additionally, the combination improved oral glucose tolerance and increased bone mineral density. Artelo Biosciences has filed a provisional patent covering ART27.13 for obesity, both as a monotherapy and in combination with GLP-1 receptor agonists.